Thiazolidinedione-induced skeletal fragility--mechanisms and implications - PubMed (original) (raw)
Review
Thiazolidinedione-induced skeletal fragility--mechanisms and implications
Andrew Grey. Diabetes Obes Metab. 2009 Apr.
Abstract
Recent evidence suggests that the risk of several types of fracture is increased in type 2 diabetes mellitus (T2DM). Thiazolidinediones (TZDs) are now widely used in the management of T2DM, and their use may increase in other diseases characterized by insulin resistance. The PPAR-gamma, the molecular target of the TZDs currently in clinical use, is expressed in skeletal tissue. Evidence from preclinical studies has demonstrated that activation of PPAR-gamma (i) inhibits bone formation by diverting mesenchymal stem cells from the osteogenic to the adipocytic lineage and (ii) may increase bone resorption by stimulating the development of osteoclasts. There is also potential for indirect adverse skeletal effects of PPAR-gamma activation by modulation of circulating levels of hormones and cytokines known to influence bone metabolism. Recent studies in humans have demonstrated that TZDs decrease markers of bone formation decrease bone mass, and increase fracture rates, at least in women. The implication of these findings is that fracture risk should be considered in patients with T2DM for whom TZD therapy is being considered, and appropriate therapy instigated to prevent fractures in individuals ascertained to be at high risk.
Similar articles
- [Thiazolidinediones and skeletal health].
Meier C, Bodmer M, Meier CR, Kraenzlin ME. Meier C, et al. Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Rev Med Suisse. 2009. PMID: 19626930 Review. French. - Bone as a target of type 2 diabetes treatment.
Lecka-Czernik B. Lecka-Czernik B. Curr Opin Investig Drugs. 2009 Oct;10(10):1085-90. Curr Opin Investig Drugs. 2009. PMID: 19777397 Review. - Skeletal consequences of thiazolidinedione therapy.
Grey A. Grey A. Osteoporos Int. 2008 Feb;19(2):129-37. doi: 10.1007/s00198-007-0477-y. Epub 2007 Sep 28. Osteoporos Int. 2008. PMID: 17901911 Review. - [Overview: derangement of bone metabolism in diabetes mellitus].
Takeuchi Y. Takeuchi Y. Clin Calcium. 2009 Sep;19(9):1247-55. Clin Calcium. 2009. PMID: 19721195 Review. Japanese. - Thiazolidinediones and fracture risk in patients with Type 2 diabetes.
Betteridge DJ. Betteridge DJ. Diabet Med. 2011 Jul;28(7):759-71. doi: 10.1111/j.1464-5491.2010.03187.x. Diabet Med. 2011. PMID: 21672000 Review.
Cited by
- Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.
Wei W, Wan Y. Wei W, et al. PPAR Res. 2011;2011:867180. doi: 10.1155/2011/867180. Epub 2011 Oct 29. PPAR Res. 2011. PMID: 22135675 Free PMC article. - iBAT on bone.
Wan Y. Wan Y. Endocrinology. 2013 Aug;154(8):2579-80. doi: 10.1210/en.2013-1514. Endocrinology. 2013. PMID: 23873771 Free PMC article. No abstract available. - Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice.
Halade GV, El Jamali A, Williams PJ, Fajardo RJ, Fernandes G. Halade GV, et al. Exp Gerontol. 2011 Jan;46(1):43-52. doi: 10.1016/j.exger.2010.09.014. Epub 2010 Oct 12. Exp Gerontol. 2011. PMID: 20923699 Free PMC article. - Prospects for osteoprogenitor stem cells in fracture repair and osteoporosis.
Clines GA. Clines GA. Curr Opin Organ Transplant. 2010 Feb;15(1):73-8. doi: 10.1097/MOT.0b013e328333d52c. Curr Opin Organ Transplant. 2010. PMID: 19935065 Free PMC article. Review. - Risk of fractures with glitazones: a critical review of the evidence to date.
Bodmer M, Meier C, Kraenzlin ME, Meier CR. Bodmer M, et al. Drug Saf. 2009;32(7):539-47. doi: 10.2165/00002018-200932070-00001. Drug Saf. 2009. PMID: 19530741 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical